Physician profile
Laurel Ann Barras
NPI 1194189787
$8,220.73
in general payments reported to CMS, 2019-2025
12 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.92 · 2020: $29.80 · 2021: $137 · 2022: $6,924 · 2023: $765 · 2024: $179 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890 · Travel and Lodging: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.17 |
| Travel and Lodging | $194.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,152.55 | 2022-2023 | |
| Stryker Corporation | $2,624.69 | 2021-2023 | Samurai, Inspace, Aequalis Flex Revive |
| Fortis Surgical, LLC | $1,200.00 | 2022 | |
| Acumed LLC | $282.96 | 2022-2023 | Acumed, Inframe Implant, Innate Implant |
| Depuy Synthes Sales INC. | $245.29 | 2020-2025 | Healix Knotless Peek, Truespan Orthocord, Orthovisc |
| Smith+Nephew, INC. | $229.01 | 2022-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| United Orthopedics LLC | $194.73 | 2023 | |
| Biorez, INC. | $108.70 | 2022 | |
| Kerecis Limited | $59.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Exactech, INC. | $56.61 | 2022 | |
| Pacira Therapeutics, INC. | $44.92 | 2019 | |
| Moximed, INC | $21.63 | 2025 | Misha Knee System, Small, Left |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Barras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.